Drug Trial Radar · NCT07791745
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
362
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Aug 30, 2032
Study completion Aug 30, 2032
Sponsor
- Lead sponsor
- Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Interventions
Enlituo® + Anyouping® + PBCDrug
Enlituo®:Enlituo® is administered according to the protocol. Anyouping®:Anyouping® is administered according to the protocol. Platinum-based chemotherapy (PBC):Cisplatin (DDP) or Carboplatin (CBP) plus Albumin-bound Paclitaxel (nab-paclitaxel) are administered according to the protocol.
Placebo-Enlituo + Anyouping® + PBCDrug
Comparator in Phase 2 is Anyouping® + PBC. Comparator in Phase 3 is Placebo-Enlituo + Anyouping® + PBC. Placebo-Enlituo (only in Phase 3):Placebo-Enlituo is administered according to the protocol. Anyouping®:Anyouping® is administered according to the protocol. Platinum-based chemotherapy (PBC):Cisplatin (DDP) or Carboplatin (CBP) plus Albumin-bound Paclitaxel (nab-paclitaxel) are administered according to the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (Phase 3)Time frame: Up to 2 years.
- Objective Response Rate (Phase 2)Time frame: Up to 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.